Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.

Giulia Orsi,Francesco Tovoli,Vincenzo Dadduzio,Caterina Vivaldi,Oronzo Brunetti,Luca Ielasi,Fabio Conti,Giulia Rovesti,Laura Gramantieri,Mario Domenico Rizzato,Irene Pecora,Antonella Argentiero,Federica Teglia,Sara Lonardi,Francesca Salani,Alessandro Granito,Vittorina Zagonel,Giorgia Marisi,Giuseppe Cabibbo,Francesco Giuseppe Foschi,Francesca Benevento,Alessandro Cucchetti,Fabio Piscaglia,Stefano Cascinu,Mario Scartozzi,Andrea Casadei Gardini

Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.

2020

An Online First version of this article was made available online at https://link.springer.com/article/10.1007/s11523-020-00757-3 on 12 October 2020. Errors were subsequently identified in the article, and the following corrections should be noted.

Keywords:

Medicine
Hepatocellular carcinoma
Internal medicine
Sorafenib
blood eosinophil
Oncology
MEDLINE
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations